Here are four quick facts:
1. Two analysts granted the shares a “buy” rating.
2. One analyst gave the shares an “outperform” rating, and another analyst gave the shares a “underperform” rating.
3. In August 2015, Jefferies analysts reiterated Orthofix International shares’ “buy” rating.
4. Jefferies has a $48 price target on Orthofix stock.
More articles on devices:
CTL Medical Corporation acquires nationally recognized medical device company, AccelSPINE
BionX Medical Technologies raises $17M in series E funding: 4 things to know
Stryker names Gary Boehnlein next VP, CFO — 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
